🚀 VC round data is live in beta, check it out!
Meditera Valuation Multiples
Discover revenue and EBITDA valuation multiples for Meditera and similar public comparables like Xtant Medical, Applied BioCode, Creo Medical Group, Farminveste and more.
Meditera Overview
About Meditera
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
Founded
1996
HQ
Employees
N/A
Website
Financials (FY)
EV
$70M
Meditera Financials
Meditera reported last fiscal year revenue of $64M and EBITDA of $5M.
In the same fiscal year, Meditera generated $20M in gross profit, $5M in EBITDA, and had net loss of ($208K).
Revenue (LTM)
Meditera P&L
In the most recent fiscal year, Meditera reported revenue of $64M and EBITDA of $5M.
Meditera expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $64M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $20M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA | — | XXX | $5M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 7% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($208K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (0%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Meditera Stock Performance
Meditera has current market cap of $79M, and enterprise value of $70M.
Market Cap Evolution
Meditera's stock price is $0.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70M | $79M | -0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeditera Valuation Multiples
Meditera trades at 1.1x EV/Revenue multiple, and 15.0x EV/EBITDA.
EV / Revenue (LTM)
Meditera Financial Valuation Multiples
As of April 8, 2026, Meditera has market cap of $79M and EV of $70M.
Equity research analysts estimate Meditera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Meditera has a P/E ratio of (379.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79M | XXX | $79M | XXX | XXX | XXX |
| EV (current) | $70M | XXX | $70M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 15.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 27.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.6x | XXX | XXX | XXX |
| P/E | — | XXX | (379.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 12.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Meditera Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Meditera Margins & Growth Rates
Meditera's revenue in the last fiscal year grew by 26%.
Meditera's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Meditera's rule of X is 80% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Meditera Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 137% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 80% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Meditera Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Xtant Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Applied BioCode | XXX | XXX | XXX | XXX | XXX | XXX |
| Creo Medical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Farminveste | XXX | XXX | XXX | XXX | XXX | XXX |
| NN | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Meditera M&A Activity
Meditera acquired XXX companies to date.
Last acquisition by Meditera was on XXXXXXXX, XXXXX. Meditera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Meditera
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMeditera Investment Activity
Meditera invested in XXX companies to date.
Meditera made its latest investment on XXXXXXXX, XXXXX. Meditera invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Meditera
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Meditera
| When was Meditera founded? | Meditera was founded in 1996. |
| Where is Meditera headquartered? | Meditera is headquartered in Turkey. |
| Is Meditera publicly listed? | Yes, Meditera is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Meditera? | Meditera trades under MEDTR ticker. |
| When did Meditera go public? | Meditera went public in 2021. |
| Who are competitors of Meditera? | Meditera main competitors are Xtant Medical, Applied BioCode, Creo Medical Group, Farminveste. |
| What is the current market cap of Meditera? | Meditera's current market cap is $79M. |
| What is the current revenue of Meditera? | Meditera's last fiscal year revenue is $64M. |
| What is the current revenue growth of Meditera? | Meditera revenue growth (vs. last FY) is 26%. |
| What is the current EV/Revenue multiple of Meditera? | Current revenue multiple of Meditera is 1.1x. |
| Is Meditera profitable? | No, Meditera is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.